NASDAQ:AVRO
AVROBIO Inc Stock News
$1.26
+0.0100 (+0.80%)
At Close: May 08, 2024
BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO
11:06am, Tuesday, 04'th May 2021
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) r
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy
09:42am, Monday, 03'rd May 2021
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
07:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provide
Rocket Pharmaceuticals Primed for Takeoff
06:19pm, Monday, 15'th Mar 2021
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe
11:56am, Monday, 01'st Mar 2021
The European Commission has designated Orphan Drug status to Avrobio Inc's (NASDAQ: AVRO) AVR-RD-04, its gene therapy to treat cystinosis. AVR-RD-04 consists of the patient's hematopoietic stem cell
Avrobio: An Update After Stock Price Drop After bluebird Trial Halt
07:11pm, Wednesday, 17'th Feb 2021
AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern.
Why Moderna, Avrobio, And More Are Moving Today
12:23pm, Monday, 08'th Feb 2021
Moderna (NASDAQ: MRNA) shares are trading higher amid South Africa stopping distribution of the AstraZeneca COVID-19 vaccine due to ineffectiveness in treating a disease variant. Moderna is working on
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
08:07am, Monday, 08'th Feb 2021
Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction,
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
07:00am, Friday, 22'nd Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announce
AVROBIO to Present at the ICR Conference 2021
07:00am, Friday, 08'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts
05:01am, Saturday, 26'th Dec 2020
AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipe
AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
10:00am, Friday, 25'th Dec 2020
AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise.